(NASDAQ: AKTX) Akari Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.91%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.23%.
Akari Therapeutics's earnings in 2026 is -$15,772,000.On average, 6 Wall Street analysts forecast AKTX's earnings for 2026 to be -$10,571,812,359, with the lowest AKTX earnings forecast at -$21,014,961,688, and the highest AKTX earnings forecast at $0.
In 2027, AKTX is forecast to generate -$11,851,294,721 in earnings, with the lowest earnings forecast at -$24,517,455,302 and the highest earnings forecast at $0.